Mohit Khera, MD, MBA, MPH

Baylor College of Medicine

Houston, Texas

Mohit Khera, MD, MBA, MPH, is a board-certified urologist specializing in male infertility, male and female sexual dysfunction, and declining testosterone levels in aging men. Dr. Khera’s research focuses on the efficacy of botulinum toxin type A in treating Peyronie’s disease as well as genetic and epigenetic studies on post-finasteride syndrome patients and testosterone-replacement therapy.

Dr. Khera earned his MBA and MPH from Boston University before earning his MD from the University of Texas Medical School at San Antonio. Dr. Khera completed his urology residency training in the Scott Department of Urology at Baylor College of Medicine (BCM) where he also completed a one-year general surgery internship. After completing his urology residency, he went on to complete a one-year fellowship in Male Reproductive Medicine and Surgery at BCM. Currently Dr. Khera is a professor in the Scott Department of Urology at Baylor College of Medicine, and he holds the F. Brantley Scott Chair in urology. Dr. Khera also serves as the director of the Laboratory for Andrology Research, the medical director of the Baylor Executive Health Program and the medical director of the Scott Department of Urology. He also serves as president of the Sexual Medicine Society of North America.

Dr. Khera has initiated numerous FDA-approved clinical trials. His scientific and clinical experiences have allowed him to thus far give over 400 lectures at scientific meetings throughout the world, publish over 160 articles in peer-reviewed journals, complete 15 book chapters, and edit and write two books in the field of sexual medicine and men’s health. Dr. Khera shares his time and knowledge with the general public. He has been voted several times as one of Houston’s Best Doctors by Health and Sport Fitness Magazine and by Houstonia Magazine and is a frequent guest on such TV programs as Fox News’ “Ask theDoctor.” He also writes a blog on men’s health for the Houston Chronicle newspaper.

Disclosures:

Talks by Mohit Khera, MD, MBA, MPH

Update on 2018 AUA Testosterone and ED Guidelines

Posted by Mohit Khera, MD, MBA, MPH | Dec 2018

Mohit Khera, MD, MBA, MPH, introduces the 2018 American Urological Association (AUA) guidelines for testosterone therapy and erectile dysfunction. He also describes inconsistencies between these guidelines and various institutions’ statements regarding these clinical areas.

Testosterone Replacement and Focal Therapy

Posted by Mohit Khera, MD, MBA, MPH | Oct 2018

Mohit Khera, MD, MBA, MPH, reviews the literature surrounding the safety of testosterone replacement therapy (TRT) following prostate cancer treatment, including after brachytherapy, EBRT, and radical prostatectomy (RP). He also discusses the concept of bipolar androgen therapy (BAT) and the importance of TRT for erectile preservation post-RP.

FDUS 2018-Next Generation General Urology and Men’s Health

Posted by Mohit Khera, MD, MBA, MPH | Sep 2018

Mohit Khera, MD, MBA, MPH, led the “Next Generation General Urology and Men’s Health” session at the Future Directions in Urology Symposium (FDUS) 2018. These consensus statements represent a comprehensive analysis of current issues, challenges, and advancements in urology from a panel of international experts.

Should Testosterone Levels Influence Decision to Biopsy?

Posted by Mohit Khera, MD, MBA, MPH | Sep 2018

Mohit Khera, MD, MBA, MPH, discusses the correlation between low testosterone levels and PSA values and lower urinary tract symptoms (LUTS). He explains the prostate saturation model and testosterone as a marker for positive prostate cancer biopsy, as well as disease progression, severity, and biochemical progression.

2018 Update on Peyronie’s Disease: What’s Around the Bend

Posted by Mohit Khera, MD, MBA, MPH | Jul 2018

Mohit Khera, MD, MBA, MPH, a panel member for the 2015 American Urological Association (AUA) Peyronie’s disease (PD) guidelines, discusses the prevalence of PD and its correlation to low testosterone. Furthermore, he summarizes the AUA statements on intralesional injections, penile stretching devices, and surgical options. He explains future directions in this setting, as well, including data from animal models testing platelet-rich plasma (PRP) and stem cells.